Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GANCICLOVIR vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including AIDS patients.,Prevention of CMV disease in transplant recipients at risk.,Treatment of CMV pneumonitis, colitis, esophagitis, and other CMV infections in immunocompromised patients (off-label).,Treatment of herpes simplex virus (HSV) infections resistant to acyclovir (off-label).
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for Cr Cl <70 m L/min
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Ganciclovir is not significantly metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration and active tubular secretion. Less than 1% is metabolized to 9-[(1,3-dihydroxy-2-propoxymethyl)guanine].
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
1-2% bound; primarily to albumin (low binding)
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.47-0.74 L/kg; indicates extensive distribution into tissues including brain, eye, and lungs
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 6-9% (fasting); increased to 30% with food due to enhanced absorption
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl ≥70 m L/min: 5 mg/kg q12h (induction), 5 mg/kg q24h (maintenance); Cr Cl 50-69: 2.5 mg/kg q12h, then 2.5 mg/kg q24h; Cr Cl 25-49: 2.5 mg/kg q24h, then 1.25 mg/kg q24h; Cr Cl 10-24: 1.25 mg/kg q24h, then 0.625 mg/kg q24h; Cr Cl <10: 1.25 mg/kg 3 times/week after hemodialysis. Oral: Cr Cl ≥70: 1000 mg tid; 50-69: 1500 mg qd or 500 mg tid; 25-49: 1000 mg qd or 500 mg bid; 10-24: 500 mg qd; <10: 500 mg 3 times/week after dialysis.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment required for hepatic impairment. Use with caution in severe hepatic dysfunction due to limited data.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral dosing in children ≥9 years: 1000 mg three times daily with food; for children <9 years, use weight-based: 30 mg/kg per dose (max 1000 mg) three times daily.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustments beyond renal function. Closely monitor renal function and adjust dose based on Cr Cl.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Ganciclovir is associated with granulocytopenia, anemia, and thrombocytopenia. Animal studies have shown that ganciclovir is carcinogenic, mutagenic, and causes impairment of fertility and teratogenicity. It is indicated only for the treatment of CMV retinitis and prevention of CMV disease in transplant recipients. Not approved for congenital or neonatal CMV disease.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Hematologic toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow suppression, especially in patients with pre-existing cytopenias or on concomitant myelosuppressive drugs.,Renal impairment: Dose adjustment required; increased risk of toxicity in renal dysfunction.,Carcinogenicity and mutagenicity: Anticipated in humans based on animal data.,Teratogenicity: Embryotoxic and teratogenic in animals; use only if benefit outweighs risk.,Interaction with mycophenolate mofetil: May increase risk of hematologic toxicity.,Electrolyte disturbances: May cause hypocalcemia, hypokalemia, hyponatremia.,Ocular effects: Retinal detachment in patients with CMV retinitis (not directly drug-related).,Seizures and neurotoxicity: Rare, especially in patients with CNS conditions or renal impairment.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to ganciclovir, valganciclovir, or any component of the formulation.,Absolute neutrophil count < 500 cells/μL, platelet count < 25,000/μL, or hemoglobin < 8 g/d L (relative contraindication due to risk of worsening cytopenias).,Pregnancy (avoid unless potential benefit outweighs risk; embryotoxic in animals).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Take ganciclovir with food to reduce gastrointestinal upset. Avoid grapefruit juice as it may increase drug levels (weak interaction). No specific food restrictions otherwise.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benefit outweighs risk. Second/third trimester: potential for bone marrow suppression and nephrotoxicity in fetus; use only if clearly needed.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Not recommended. M/P ratio unknown; ganciclovir is excreted into breast milk in rats. Potential for severe adverse effects in nursing infant (e.g., bone marrow suppression, carcinogenesis).
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific pregnancy dosing adjustments established. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; monitor drug levels if available. Standard dosing: 5 mg/kg IV q12h x 14-21 days (induction), then 5 mg/kg/day (maintenance). Adjust for renal function (Cr Cl). Use lowest effective dose.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Monitor renal function closely; dose adjustment required in renal impairment. Ganciclovir is myelosuppressive; check CBC frequently, especially in patients with neutropenia. Use with caution in patients with pre-existing cytopenias. Administer IV infusion over at least 1 hour to reduce renal toxicity. Valganciclovir, the prodrug, is only for CMV retinitis in immunocompromised patients. Always maintain adequate hydration to prevent crystalluria.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Ganciclovir may lower your blood cell counts, increasing risk of infection, bleeding, or anemia. Report any signs of infection (fever, chills), unusual bruising/bleeding, or fatigue immediately.,Keep all appointments for blood tests and kidney function monitoring.,Drink plenty of fluids to prevent kidney problems.,Use effective contraception during treatment and for at least 30 days after stopping for females, and for 90 days for males; ganciclovir can harm an unborn baby.,Do not breastfeed during treatment due to potential harm to the infant.,Avoid driving or operating machinery if you experience dizziness, confusion, or seizures.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Probenecid inhibits renal tubular secretion of ganciclovir, reducing its clearance and increasing its plasma concentration. This can potentiate the antiviral effect but also elevates the risk of dose-dependent adverse effects such as myelosuppression and nephrotoxicity. Concurrent use may require dose adjustment of ganciclovir and monitoring for toxicity."
"Combined use of ganciclovir and zidovudine results in additive myelosuppression, particularly neutropenia and anemia, due to overlapping bone marrow toxicity. This interaction increases the risk of severe hematologic adverse effects, including life-threatening infections and transfusion-dependent anemia. Patients with pre-existing cytopenias or those receiving other myelotoxic agents are at heightened risk."
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Zalcitabine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GANCICLOVIR vs ABSTRAL, answered by our medical review team.
GANCICLOVIR is a Antiviral that works by Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GANCICLOVIR and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GANCICLOVIR is: Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GANCICLOVIR and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GANCICLOVIR is classified as Category D/X. FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benef. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.